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2 The Journal of Thoracic and Cardiovbjectives: Proliferating cell nuclear antigen is a component of the DNA synthe-
ome and functions in DNA replication and repair. Our group has recently identified
n acidic isoform of proliferating cell nuclear antigen, cancer-specific proliferating
ell nuclear antigen, that appears to be present only in malignant tissue. We sought
o determine the presence of cancer-specific proliferating cell nuclear antigen in
sophageal dysplasias and invasive adenocarcinomas to assess its potential utility in
iscriminating malignancy.
ethods: With a polyclonal antibody to cancer-specific proliferating cell nuclear
ntigen, immunohistochemical staining was performed on samples from a total of
0 patients with Barrett esophagus with varying degrees of dysplasia and 18 patients
ith invasive adenocarcinoma. We also performed cancer-specific proliferating cell
uclear antigen immunohistochemical staining on a commercially available tissue
icroarray and on specimens obtained from endoscopic biopsies. As controls,
mmunohistochemical staining for cancer-specific proliferating cell nuclear antigen
as performed on normal esophageal tissue and immunohistochemical staining for
roliferating cell nuclear antigen was performed on all specimens with a commer-
ially available antibody.
esults: Of the Barrett esophagus specimen, 14 showed no dysplasia, 8 showed
ow-grade dysplasia, and 8 showed high-grade dysplasia. None of these specimens
tained positively for cancer-specific proliferating cell nuclear antigen. Of the 18
denocarcinoma specimens, all stained positively for cancer-specific proliferating
ell nuclear antigen. There was no significant cancer-specific proliferating cell
uclear antigen expression in normal esophageal tissue, and proliferating cell
uclear antigen expression was noted to a high degree in all tissues.
onclusions: Cancer-specific proliferating cell nuclear antigen appears to demon-
trate high specificity for esophageal adenocarcinoma. This marker therefore may
rove useful in differentiating invasive cancer from high-grade dysplasia. Cancer-
pecific proliferating cell nuclear antigen also holds future promise as a biomarker
or esophageal adenocarcinoma.
uring the past two decades, the incidence of esophageal adenocarcinoma
has increased in many countries, including the United States, at a rate
exceeding that of any other malignancy.1 Currently, adenocarcinoma of the
istal esophagus represents 60% to 90% of all esophageal cancers. Esophageal
denocarcinoma, like other malignant processes, develops as a result of a multistep
rocess requiring the accumulation of multiple genetic mutations. This process
ltimately results in a cell that is independent of regulated proliferative and cell
eath pathways and that has the capacity to become invasive and metastasize.
lthough the precise mechanisms are unknown, it is thought that the transformation
ascular Surgery ● January 2007
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TSf a normal cell to a malignant one is dependent on an
ncreased level of genetic alteration that leads to genomic
nstability.2
An additional mechanism by which genetic alterations
ay occur is an error-prone DNA replication process. In the
ormal cell, DNA replication occurs with great fidelity,
hereas DNA replication in malignant cells tends to be
rror prone.3 During replication, one or more of the com-
onents of the DNA replication process may become altered
nd thus lead to genetic mutations in the malignant cell. An
ncrease in the error frequency associated with the DNA
ynthetic machinery responsible for the elongation of a
ell’s DNA could result in the accumulation of mutations.
uman cell DNA replication requires the coordinated ac-
ivity of a number of components. It has been demonstrated
hat this coordinated activity is mediated by a physically and
unctionally organized multiprotein complex termed the
NA synthesome.4 It has also been demonstrated that the
ynthesome derived from malignant cells mediates error-
rone DNA replication.3 Thus alterations in the DNA syn-
hesome, leading to error-prone DNA replication, point to a
ossible mechanism by which a normal cell is transformed
nto a malignant cell.
Proliferating cell nuclear antigen (PCNA) is a component of
he DNA synthesome and functions in DNA replication and
epair.2 It has been shown that a unique form of PCNA,
ancer-specific PCNA (csPCNA), is found in all malignant
reast cells but not in nonmalignant breast cells.3 Therefore
sPCNA may serve as a biomarker of malignancy. A poly-
lonal antibody that allows the detection of csPCNA by im-
unohistochemical staining has been developed by our labo-
atory and designated csPCNAab. We sought to determine
hether csPCNA might distinguish nonmalignant esophageal
issue from esophageal adenocarcinoma to explore the possi-
ility that csPCNA represents a novel biomarker for the de-
ection of esophageal adenocarcinoma.
ethods
reparation of csPCNAab
abbit polyclonal antibodies were prepared by a commercial ven-
or (Zymed Laboratories Inc, South San Francisco, Calif) to a
eptide fragment of PCNA coupled to keyhole limpet hemacyanin
Abbreviations and Acronyms
csPCNA  cancer-specific proliferating cell nuclear
antigen
csPCNAab polyclonal antibody to cancer-specific
proliferating cell nuclear antigen
KLH  keyhole limpet hemacyanin
PBS  phosphate-buffered saline solution
PCNA  proliferating cell nuclear antigenKLH) through four cysteine residues added to the amino-terminal r
The Journal of Thoracortion of the peptide. A 100-g portion of the KLH conjugated to
peptide fragment of PCNA contained within amino acids 112
hrough 150 of the protein was resuspended in complete Freund
djuvant and injected subcutaneously into multiple sites in two
emale New Zealand White rabbits. The rabbits were rested for 1
onth before boosting with a second 100-g dose of the KLH-
oupled antigen in incomplete adjuvant. Antibody titer to the
ntigen was determined by enzyme-linked immunosorbent assay
pproximately 10 to 14 days after immunization, and after an
dditional 14-day rest period the animals received another boost
f KLH-coupled antigen. Twelve days later, 25 mL antiserum was
ollected from each rabbit and stored at 20°C. The antiserum
as dialyzed against two changes of 20-mmol/L phosphate-
uffered saline solution (PBS), pH 7.0, and loaded onto a protein
Sepharose column (Amersham Pharmacia Biotech AB, Uppsala,
weden) equilibrated in advance with the PBS. The binding
apacity of the gel is 19 mg rabbit immunoglobulin G/mL packed
el bed. The column was washed with 10 column volumes of PBS
nd eluted with 10 volumes of 0.1-mol/L glycine buffer, pH 3.0.
hen 1-mL fractions eluting from the column were collected at a
owrateof1to2mL/mininto0.25mL0.25-mol/Ltris(hydroxymethyl)
minomethane hydrochloride, pH 8.0. The concentration of protein
n fractions containing the protein peak eluting from the column
as determined by Bradford assay, and these fractions were com-
ined and dialyzed against PBS containing 10-mmol/L sodium
zide before being stored at 4°C until their use in various assays.
mmunohistochemical Staining
araffin sections (4 m) taken on charged slides were deparaf-
nized in xylene (three changes) and hydrated with graded alco-
ols and distilled water. Antigen retrieval was performed in citrate
uffer (pH 6.0) in a microwave oven for 10 minutes with subse-
uent cooling for 20 minutes. This was followed by blocking of
ndogenous peroxidase activity with Peroxo-block (Zymed). After
insing slides in PBS, the slides were incubated with the csPCNA
ntibody (dilution 1:400) for 1 hour. The antigen–antibody reac-
ion was visualized by the avidin-biotin-peroxidase (Picture Plus
it: HRP/Fab polymer conjugate; Zymed) with diaminobenzidine
DABplus; DAKO Corporation, Carpinteria, Calif) as the chromo-
en. These were counterstained with hematoxylin (Vector Labo-
atories, Inc, Burlingame, Calif). These sections were then cleared
n alcohol and xylene. The slides were then mounted with Histo-
ount (Zymed) and visualized. Substitution of primary antibody
y PBS or isotype control antibody was done for negative control
reparations.
Immunohistochemical staining was performed on archived,
araffin-embedded tissue from specimens available at the Indiana
niversity Medical Center. In addition, staining for csPCNA was
erformed on a commercially available tissue microarray consist-
ng of 60 invasive esophageal adenocarcinoma samples and 3
amples of normal esophageal squamous mucosa (US Biomax,
nc, Ijamsville, Md). Immunohistochemical staining for PCNA
as performed with the commercially available PC10 antibody
PCNA Staining Kit; Zymed).
The study was approved by the Indiana University institutionaleview board.
ic and Cardiovascular Surgery ● Volume 133, Number 1 83
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TSesults
total of 48 archived, paraffin-embedded samples of ab-
ormal esophageal tissue were examined. These samples
ame from 14 cases of Barrett esophagus (BE) without
istologic evidence of dysplasia, 8 cases of BE with low-
rade dysplasia, 8 cases of BE with high-grade dysplasia,
nd 18 cases of invasive esophageal adenocarcinoma.
mong the 30 BE specimens, none stained positively for
sPCNA (Figure 1). Among the 18 adenocarcinoma speci-
ens, all stained positively for csPCNA (Figure 2). All 48
pecimens stained positively for PCNA with the commer-
ially available antibody.
In the tissue microarray, all the adenocarcinoma speci-
ens stained positively for csPCNA, whereas there was no
ignificant csPCNA staining of the normal squamous mu-
osa. Finally, csPCNA staining was performed on various
pecimens obtained by endoscopic biopsy. All adenocarci-
oma specimens stained positively for csPCNA, whereas
one of the BE specimens stained positively.
As a control run, 10 specimens of normal esophageal
quamous cell mucosa were examined. There was no sig-
ificant csPCNA staining of these specimens, whereas all
tained positively for PCNA (figure 3).
iscussion
CNA is associated with the human cell DNA synthesome
nd is required for synthesome-mediated DNA replication
n vitro. PCNA is a cofactor for DNA polymerase , which
s essential for mammalian DNA replication and repair.5 It
s maximally expressed in the nuclei of late G1-S phase
ells and has therefore been used as an indicator of the rate P
4 The Journal of Thoracic and Cardiovascular Surgery ● Januaf cell proliferation. High expression of PCNA has been
hown to correlate with poor prognosis for several solid
umors.6-8 Other studies, however, have failed to demon-
trate such a correlation. Bechtel and colleagues9 used
reast cancer cell lines to demonstrate that PCNA exists in
wo isoforms, an acidic form and a basic form. They also
emonstrated that the acidic form was unique to malignant
ells, whereas the basic form could be detected in both
alignant and nonmalignant cells. They also showed that
he acidic form, now known as csPCNA, was likely the
esult of an alteration in the posttranslational modification
f PCNA, because it was neither proliferation dependent nor
he result of a genetic alteration. Further work by our group
as led to the isolation of csPCNA and to the development
f a polyclonal antibody that can detect this isoform.
With immunohistochemical staining, we have been able
o demonstrate that this unique form of PCNA, csPCNA, is
etectable in esophageal adenocarcinoma but in neither any
f its precursor lesions (BE with varying degrees of dyspla-
ia) nor normal esophageal squamous mucosa. A polyclonal
ntibody, csPCNAab, successfully detected csPCNA in ade-
ocarcinoma, whereas the basic isoform of PCNA was
etected in all tissues with a commercially available anti-
ody. These findings lend further support to previous re-
orts that indicate that csPCNA is detectable only in ma-
ignant tissues. Therefore csPCNA may be a marker of
alignancy, although much work remains in validating this
arker and in assessing its specificity in various tissues.
Our results further suggest that esophageal adenocarci-
oma has an altered DNA replication mechanism and that
Figure 1. Negative staining for cancer-
specific proliferating cell nuclear anti-
gen in 2 separate high-grade dysplasia
specimens.CNA alterations may play a role in carcinogenesis. The
ry 2007
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G
TSetection of csPCNA in esophageal adenocarcinoma may
llow earlier detection of this type of malignancy. Cur-
ently, histologic evaluation is the only means by which
ysplastic changes, most prominently high-grade dysplasia,
re differentiated from invasive adenocarcinoma. Although
n most cases this is an easy determination, it may some-
imes be difficult and subject to pathologic interpretation.
y using csPCNA, it may be possible to make such a
etermination conclusively. When it is difficult to distin-
uish high-grade dysplasia from invasive adenocarcinoma,
ositive staining with csPCNA will lend support to the
iagnosis of invasive adenocarcinoma, or negative staining
ill support the diagnosis of high-grade dysplasia only.The Journal of Thoracurthermore, it is widely held that as many as 30% of high
rade dysplasias contain foci of invasive cancer; positive
taining with csPCNA could help to identify such cases
onclusively, potentially sparing patients from invasive
rocedures designed to treat invasive cancer even in the
bsence of histologically identifiable cancer on biopsy
esophagectomy).
There are several limitations to our study. Although the
etection of csPCNA in esophageal adenocarcinomas by
mmunohistochemical staining is highly suggestive of alter-
tions in this protein and the DNA replicative machinery,
uch alterations can only be confirmed by the careful iso-
ation and analysis of the DNA replication apparatus in
Figure 2. Positive staining for cancer-
specific proliferating cell nuclear anti-
gen in 2 separate specimens of inva-
sive esophageal adenocarcinoma.
Figure 3. Positive staining for prolifer-
ating cell nuclear antigen (A) and neg-
ative staining for cancer-specific pro-
liferating cell nuclear antigen (B) in
normal esophageal squamous mucosa.ic and Cardiovascular Surgery ● Volume 133, Number 1 85
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G
TSsophageal adenocarcinoma cells. During our immunostain-
ng, we encountered isolated instances of positive csPCNA
taining in histologically nonmalignant tissue. The staining
attern in these cases differed slightly between tissue ob-
ained by formal resection and tissue obtained by endo-
copic biopsy, indicating a possible effect of tissue prepa-
ation on the specificity of csPCNA detection. Although
uch staining of nonmalignant tissue may indicate nonspe-
ific staining by the csPCNAab, other possibilities include
he detection of early malignant changes in histologically
onmalignant-appearing cells as well as an effect of tissue
reparation, such as the amount of hypoxic time, on alter-
tions of PCNA. These issues are currently the focus of
urther investigations into the specificity of the csPCNAab
cross many tissue types. It should be emphasized, however,
hat the detection of csPCNA in nonmalignant tissue has
een limited, whereas all malignant tissues have stained
ositively for csPCNA.
Taken together, these preliminary studies suggest that
sPCNA may be a marker for esophageal adenocarcinoma.
f confirmed by future studies, this finding would have great
mplications for the treatment of patients with cancer. By
sing the csPCNAab to follow the status of csPCNA, it may
e possible to monitor the response of individual patients to
eoadjuvant chemoradiation, with the lack of detection sig-
ifying a pathologically complete response. If this tech-
ique is proved reliable for the detection of pathologically
omplete response, it may then be possible to perform a trial
omparing the outcomes of patients with pathologically
omplete response with and without surgery. It may also be
ossible to diagnose cancer at an early stage, concealed
ithin high-grade dysplasia. The csPCNAab may become a
seful member of a panel of antibodies that have the ability
o recognize markers currently used to evaluate tumors for
heir malignant potential, yielding a prognosis. Finally, the
sPCNAab may be a useful reagent for developing enzyme-
inked immunosorbent assays and immunohistochemical as-
ays for screening purposes.
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iscussion
r Michael Weyant (Denver, Colo). Dr Hammoud, congratula-
ions on your article. I enjoyed reading it, and I appreciate you
ending it to me well ahead of the date of this meeting.
You and your coauthors have found a unique biomarker iden-
ifying and isolating malignant cells in esophageal tissue. I think
ndings such as these are important not only because of the ability
o mark a cell but also because they can eventually provide some
nsight into the biology of the cancer cell itself. You also were able
o show us a method that is applicable immediately globally to all
athologists, and I think that is important. But I have a few
uestions for you.
First, given that a pathologist on a routine hematoxylin and
osin stain can identify a cancer cell on the basis of its nuclear
orphology, and you have basically to have the presence of the
ancer cell to identify it, how is your technique an actual improve-
ent over those already known methods?
Dr Hammoud. I alluded to this earlier. I think a lot of times the
ifferentiation between high-grade dysplasia and invasive carci-
oma is difficult and is pathologist dependent. I think the greatest
tility right now of having this antibody is in exactly those sce-
arios. I agree wholeheartedly that you don’t need this antibody to
iagnose cancer, at least not on a biopsy or a tissue specimen, but
think in those difficult cases it can help. I foresee this as basically
eing a member of a panel of antibodies that we might be able to
se to form some prognostic indicators or, as I said, for those cases
here one cannot differentiate high-grade dysplasia from invasive
ancer. I think the really exciting potential, however, is the ability
o diagnose or pick up csPCNA in the serum. I think that’s where
he money is, and that’s where the biggest clinical impact is
otentially going to be.
Dr Weyant. For my second question, and you alluded to this in
our article, one of the important applications I see is in looking at
roups of patients who have been treated and determining the level
f treatment response. We have a group of patients who are
etermined to have complete response on the basis of pathologic
nalysis, and they are thought to have a better prognosis. Yet they
on’t survive forever. I think that with your technique we can
tratify groups of these patients. Because these tissues came from
our tissue bank at the university, have you had the opportunity to
valuate those patients and their responses to their specific treat-
ents?
Dr Hammoud. The short answer is no; however, we have an
nstitutional Review Board–approved prospective study underway
ight now. As at many other institutions, most of our patients,
robably 90%, are getting neoadjuvant chemoradiation. Our pro-
ocol attempts to predict which patients have a complete patho-
ogic response. At restaging endoscopic ultrasonography after the
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G
TSompletion of neoadjuvant therapy, if no visible tumor is seen, the
ndoscopist will perform four quadrant biopsies in the area where
he tumor had been seen before treatment. Patients go on to
urgical resection, and if in fact they have had a complete patho-
ogic response we can go back and take a look and see whether we
ould have predicted that complete pathologic response by staining
or csPCNA. As you know, 25% to 30% of patients will have a
omplete pathologic response after their neoadjuvant therapy, and
he only way to know that is to take the esophagus out. We would
ike to see whether by using this antibody we can reliably predict
hich patient has had a complete pathologic response.
Dr Weyant. Great work. Thank you very much.
Dr Hammoud. Thank you.
Dr Donald Low (Seattle, Wash). Once again, I congratulate
ou on your work. It is potentially another step in the modalities
e are all going to be using to determine which patients require
hat types of treatment. To that end, specifically, one of the issues
e’re all dealing with right now is that for patients we believe to
ave true high-grade dysplasia or even intramucosal cancer, we’re
eighing with risks and benefits of endoscopic versus surgical
herapy. One of the things that comes to mind regarding your
echnique is the ability to increase accuracy of interpretation of the
resence or absence of cancer cells up to or through the lamina
ropria. Have you begun to use this type of technology to increase
he acuity of this assessment in presurgical patients, so that we can
egin to apply the endoscopic modalities more appropriately?
Dr Hammoud. No, but that is obviously the goal. As I stated
n my comments, this is a work in progress. The first goal is for us
o try to make a monoclonal antibody. We know from antibodies
n general that monoclonals tend to be better than polyclonals.
hey are certainly easier to work with in terms of developing
mmunohistochemical conditions, but I agree with you. That is
xactly where the clinical applicabilities of this type of antibody
ie, and that is where the future is. We also struggle with—and I’m
ure a lot of people in this room have similar experiences to us—a m
The Journal of Thoracot of the T1 cases not making it to us. They are just being treated,
nd it’s not right, but it happens. It happens in the communities,
nd it happens at our university even though we beg and plead and
ell everybody that these things need to be handled in a true
ultidisciplinary fashion, but that’s the reality. We just talked in
he previous discussion about how lung cancers get treated without
ny of our input. A lot of these T1 and high-grade dysplasia cases
re being treated without our input, and needless to say somebody
ho does that generally doesn’t know about this technology or
ow they can potentially improve patient outcome.
Dr Richard Whyte (Stanford, Calif), Thanks for an interesting
resentation. One of the comments you made, or suggested, was
hat the problem of separating invasive carcinoma from high-grade
ysplasia was related to the pathologist reading the slide. I think
hat this particular issue is more a sampling issue, whereas an
nterpretative or pathologist-specific issue is distinguishing low-
rade from high-grade dysplasia, where as you know there is a
reat deal of interobserver variability.
My question to you, though, has to do with the role of this
iomarker in either screening patients with Barrett esophagus or
iscriminating patients with progression from low-grade to high-
rade dysplasia or from high-grade dysplasia to invasive adeno-
arcinoma. Do you have any data on cytologic analysis with this
echnique?
Dr Hammoud. No. This marker is really present in malignant
issue. The only thing we’ve shown thus far is its presence in
rankly malignant tissue. In both low-grade dysplasia and high-
rade dysplasia, none of specimens was stained by this antibody,
o it would not be helpful in that regard. Whether we can show
ifferences between high- and low-grade dysplasias is something
hat I’m working on right now with serum proteomics. I’m looking
t normal tissue, low-grade dysplasia, high-grade dysplasia, and
ancers and trying to determine protein patterns in serum that
ight help us spot that progression.
ic and Cardiovascular Surgery ● Volume 133, Number 1 87
